What is Avalo Therapeutics Inc's share price today?
Avalo Therapeutics Inc (AVTX) share price today is $7.45 as of October 23, 2026 at 1:30 AM IST. The stock touched a day high of $8.46 and a day low of $6.89.What exchange does Avalo Therapeutics Inc stock trade on, and under what ticker symbol?
Avalo Therapeutics Inc stock trades on NASDAQ under the ticker symbol AVTX.What is Avalo Therapeutics Inc's market capitalization?
Avalo Therapeutics Inc's market capitalization is $662.86M as of October 23, 2026 at 1:30 AM IST.What is Avalo Therapeutics Inc's price-to-earnings (P/E) ratio?
Avalo Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of October 22, 2026.What is Avalo Therapeutics Inc's price-to-book (P/B) ratio?
Avalo Therapeutics Inc's price-to-book (P/B) ratio is 1.82 as of October 22, 2026.Can Indian investors buy Avalo Therapeutics Inc shares?
Yes, You can buy Avalo Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Avalo Therapeutics Inc shares from India?
Indian investors can buy Avalo Therapeutics Inc shares in three steps: 1. Search Avalo Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Avalo Therapeutics Inc shares for Indian investors?
Since Avalo Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Avalo Therapeutics Inc shares via Tickertape?
Indian investors can start investing in Avalo Therapeutics Inc (AVTX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.3422 shares at the current price of $7.45.
$
₹
$7.4539.23% (-4.81)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
1.82
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-4.31
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 14 analysts reports
Buy14 analysts
Hold0 analyst
Sell0 analyst
Price Upside
+259.57%
Earnings Growth
+52.4%
Rev. Growth
—
Company Profile
Company Profile
ABBV
P/E Ratio
81.66
81.66
1Y Return
24.54%
24.54%
Buy Reco %
80.00
80.00
AMGN
P/E Ratio
27.26
27.26
1Y Return
49.15%
49.15%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
29.41%
29.41%
Buy Reco %
78.57
78.57
P/E Ratio
29.80
29.80
1Y Return
25.49%
25.49%
Buy Reco %
81.25
81.25
MRNA
P/E Ratio
—
—
1Y Return
654.67%
654.67%
Buy Reco %
21.73
21.73
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$12.26Baseline
Analyst Target - 1 year
Target$44.08+259.57%
All values in $
2026
Current$12.26Baseline
Analyst Target - 1 year
Target$44.08+259.57%
All values in $
Earnings Per Share Forecast
Earnings Per Share Forecast
2025
Current$-5.73Baseline
Forecast for Dec 2026
High$-2.18+61.95%
Average$-2.73+52.4%
Low$-3.06+46.6%
All values in $
2025
Current$-5.73Baseline
Forecast for Dec 2026
High$-2.18+61.95%
Average$-2.73+52.4%
Low$-3.06+46.6%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0.24 | 0.19 | 0 | 0 | 0 | 0.05 | 0 | 0 |
| Gross Profit | 0.04 | -0.34 | 0.96 | 0.10 | -5.91 | -10.66 | -9.99 | 0.05 | -0.01 | - |
| Net Income | -121.29 | 98.46 | 23.03 | -35.33 | -13.14 | -20.76 | -30.62 | -13.72 | -19.63 | -36.35 |
| Net Profit Margin | - | - | 9251.80% | -18405.72% | - | - | - | -23254.23% | - | - |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Avalo Therapeutics Inc | - | 1.82 | - |
| AbbVie Inc | 81.66 | 50.45 | 0.54 |
| Amgen Inc | 27.26 | 18.78 | 2.45 |
Price Comparison
Price Comparison
Compare AVTX with any stock or ETFCompare AVTX with any stock or ETF
Comparing from
AVTX
ABBV
AMGN
The 12-month consensus target implies 259.57% growth, versus a trailing 3-year CAGR of -24.82%.